Skip to main
BLLN

Billiontoone Inc (BLLN) Stock Forecast & Price Target

Billiontoone Inc (BLLN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

BillionToOne is attractive because its QCT platform and single-molecule quantification create differentiated prenatal and oncology assays that address real workflow pain points, including UNITY’s one-blood-draw fetal risk screening and Northstar’s ultrasensitive liquid biopsy capabilities. Fundamentally, the company is converting that technology edge into commercial traction, with Q1'26 revenue of $108.4M (+84% Y/Y), 73% gross margin, 16% GAAP operating margin, $537M of cash, and total payer coverage reaching ~300M lives after Anthem and UnitedHealthcare wins. The positive outlook is further supported by conservative guidance that still calls for 2026 revenue of $450M-$465M and 70%+ gross margins, while new launches like UNITY Confirm and the planned MRD test expand the runway across very large prenatal and oncology markets.

Bears say

BillionToOne is facing a weaker fundamental setup because Q2'26 showed solid 64% revenue growth to $109.4M, but operating expenses surged 59% to $72M as management pulled forward sales hiring, causing Adj. EBITDA of $16.1M and GAAP EPS of $0.15 to miss expectations. Despite $549M of cash and positive $5.1M FCF, the company reaffirmed 2026 revenue guidance of $450M-$465M while forecasts for 2026-2028 were cut, with higher opex and only modest gross margin support limiting leverage. The bearish view is further supported by dependence on complex reimbursement and billing processes, concentration in molecular diagnostics, and uncertainty around how durable UNITY’s ~15% prenatal market share and newer oncology products will be against competition and execution risk.

Billiontoone Inc (BLLN) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Billiontoone Inc (BLLN) Forecast

Analysts have given Billiontoone Inc (BLLN) a Buy based on their latest research and market trends.

According to 8 analysts, Billiontoone Inc (BLLN) has a Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Billiontoone Inc (BLLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.